Local Time : 10:15 CET

C-3088 - Application of apparent diffusion coefficient in magnetic resonance imaging in an assessment of the early response to treatment in Hodgkin’s and non-Hodgkin’s lymphoma

A. Pawluś, J. Kwiatkowski, M. Patyk, D. Holownia, K. B. Szymańska, D. Sokołowska-Dąbek, R. Mazur, M. Kuliszkiewicz-Janus, U. Zaleska-Dorobisz; Wroclaw/PL Type: Scientific Exhibit
Area of Interests: Lymph nodes, Oncology, Hematologic
Imaging Technique: MR-Diffusion/Perfusion
Procedure: Computer Applications-Detection, diagnosis
Special Focus: Lymphoma
Add poster to my schedule In your schedule (remove)

Aims and objectives: Introduction: Lymphoproliferative neoplasms are the largest and most frequently diagnosed entities in the group of haematological malignancies [1]. Over the years an increasing trend of incidence rate of lymphomas has been noticed. Currently it amounts to approximately 20-22 new cases per 100,000 pe[...]

Methods and materials: The study included the final group of 27 patients with the Hodgkin’s and non-Hodgkin’s lymphoma diagnosed. (Tab. 1) They underwent MRI of the area in question before the treatment and on the first day of the second cycle of chemotherapy. All examinations were performed using a 1.5T MR unit with a co[...]

Results: There was a statistically significant difference between the ADC values in the pre-treatment (ADC=720 mm2/s) and post-treatment (ADC=1059 mm2/s) studies (Fig. 3.). The ADC value increased significantly in both groups (Tab. 2). In the group of the patients with diagnosed Hodgkin’s lymphoma the ADC in[...]

Conclusion: Measurements of the ADC values before treatment and on the first day of the second cycle of chemotherapy can be used as a prognostic marker in therapy of lymphomas. The most promising tool for assessing response to treatment seems to be ratio between the ADC value measured in the area of infiltrati[...]

Personal information:

References: [1]         B. D. Cheson et al., “Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The lugano classification,” J. Clin. Oncol., vol. 32, no. 27, pp. 3059–3067, 2014. [2]      [...]

This website uses cookies. Learn more